Mouse study links an amyloid-beta surge after injury to chronic pain

A mouse study has identified amyloid-beta 42, a peptide best known for its role in Alzheimer’s disease, as a possible driver of the transition from acute to persistent pain after injury. The work was published September 2 in *Science Translational Medicine*.

Researchers found that tissue injury altered metabolism in spinal-cord oligodendrocytes, the cells responsible for producing and maintaining myelin around nerve fibers. The resulting cascade disrupted myelin and axonal integrity, increased neuronal production of amyloid-related proteins and raised insoluble amyloid-beta 42 during the period when temporary pain-related behavior became persistent.

Pharmacological and genetic interventions that interrupted this pathway prevented prolonged hypersensitivity in the animals while preserving their immediate response to injury. That result strengthens the mechanistic case but remains entirely preclinical: the study did not enroll people, test a clinical pain treatment or establish that amyloid biology has the same role in human chronic pain.

Following the transition after tissue injury

The researchers induced peripheral injury with a formalin injection into the hind paw of mice. Single-nucleus RNA sequencing showed that spinal oligodendrocytes reduced expression of genes involved in myelin-protein production while increasing genes involved in lipid synthesis. Lipid analyses indicated that those resources were being redirected away from normal myelin maintenance.

The investigators then observed impaired axonal integrity, accumulation of amyloid precursor protein in neurons and increased expression of BACE1, an enzyme involved in generating amyloid-beta. Insoluble amyloid-beta 42 rose during a critical interval preceding persistent pain-related hypersensitivity.

These measurements establish a sequence of associated biological changes. Because the experiments were performed in controlled mouse injury models, however, they cannot determine how often this pathway operates after surgery, trauma or nerve injury in people. Behavioral hypersensitivity in mice is also an experimental proxy rather than a direct measure of the multidimensional experience of human chronic pain.

Several interventions tested causality

To assess whether amyloid-beta 42 was contributing to the phenotype rather than merely appearing alongside it, the team disrupted the pathway in several ways. Inhibiting BACE1 reduced amyloid-beta production, while an intrathecally administered 4G8 monoclonal antibody was used to clear or neutralize amyloid-beta in the spinal compartment. Genetic approaches also interfered with amyloid precursor protein production.

Across these approaches, blocking the amyloid pathway during the post-injury window prevented persistent hypersensitivity without eliminating the initial acute response. The researchers further examined N-acylethanolamine acid amidase, or NAAA, an enzyme that regulates lipid metabolism and pain signaling. Removing NAAA specifically from oligodendrocytes prevented the amyloid-beta increase and chronic pain-related behavior after formalin injury.

That genetic result was reproduced in a second model involving sciatic-nerve ligation, reducing the likelihood that the proposed mechanism was unique to the formalin experiment. Multiple converging interventions provide stronger causal evidence within mice than an observational molecular association alone.

What the result does not establish

The study does not demonstrate that Alzheimer’s disease causes chronic pain or that people with persistent pain are developing Alzheimer’s pathology. It identifies a localized amyloid-related process in the mouse spinal cord, not a diagnosis of neurodegenerative disease.

Nor does it support using approved or experimental anti-amyloid medicines after an injury. The antibody intervention was delivered directly into the spinal compartment, and the safety, timing and feasibility of modifying this pathway in people remain unknown. Amyloid precursor proteins and related enzymes have normal biological functions, making unintended effects an important translational concern.

The practical advance is a testable mechanism: injury may push oligodendrocytes away from myelin maintenance, compromise axons and trigger neuronal amyloid-beta 42 production that helps consolidate persistent pain-related behavior. Human tissue studies and prospective clinical research will be needed to determine whether the same sequence occurs in patients and whether it can be modified safely.